Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?

被引：1
|
作者：
Eguren-Santamaria, Inaki [1 ,2 ]
Sanmamed, Miguel F. [1 ,2 ,3 ,4 ]
Gil-Bazo, Ignacio [1 ,3 ,4 ,5 ]
机构：
[1] Clin Univ Navarra, Dept Oncol, Pamplona 31008, Spain
[2] Univ Navarra, Program Immunol & Immunotherapy, Ctr Appl Med Res, Pamplona, Spain
[3] Navarra Inst Hlth Res, IdiSNA, Pamplona, Spain
[4] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[5] Univ Navarra, Program Solid Tumors, Ctr Appl Med Res, Pamplona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 04期
关键词：
CELL LUNG-CANCER; DOCETAXEL; BRAF;
D O I：
10.1016/j.jtho.2020.02.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：489 / 492
页数：4
相关论文
共 50 条
  • [1] Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma
    Kwok, Hoi-Hin
    Yang, Jiashuang
    Lam, David Chi-Leung
    [J]. CANCERS, 2023, 15 (10)
  • [2] When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
    Laurent Mhanna
    Nicolas Guibert
    Julie Milia
    Julien Mazieres
    [J]. Current Treatment Options in Oncology, 2019, 20
  • [3] When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
    Mhanna, Laurent
    Guibert, Nicolas
    Milia, Julie
    Mazieres, Julien
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (07)
  • [4] TYROSINE KINASE INHIBITORS AS A TREATMENT OF SYMPTOMATIC CNS METASTASES IN ONCOGENE-DRIVEN NSCLC
    Benouaich-Amiel, Alexandra
    Gal, Omer
    Dudnik, Elizabeth
    Rotem, Ofer
    Finket, Inbar
    Peretz, Idit
    Zer, Alona
    Mandel, Jacob
    Siegal, Tali
    Bar, Jair
    Yust-Katz, Shlomit
    [J]. NEURO-ONCOLOGY, 2020, 22 : 1 - 1
  • [5] Targeting Residual Disease in Oncogene-Driven NSCLC
    McCoach, C. E.
    Merrick, D. T.
    Aisner, D. L.
    Bunn, P. A.
    Camdige, D. R.
    Heasley, L. E.
    Doebele, R. C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (08) : S1546 - S1546
  • [6] Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
    Gal, Omer
    Dudnik, Elizabeth
    Rotem, Ofer
    Finkel, Inbar
    Peretz, Idit
    Zer, Alona
    Mandel, Jacob
    Amiel, Alexandra
    Siegal, Tali
    Bar, Jair
    Lobachov, Anastasiya
    Yust, Shlomit
    [J]. JOURNAL OF ONCOLOGY, 2020, 2020
  • [7] Systemic Therapy for Advanced Oncogene-Driven NSCLC
    Gandara, David R.
    Popat, Sanjay
    Melosky, Barbara
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S51 - S52
  • [8] Perioperative targeted therapy for oncogene-driven NSCLC
    Liu, Si -Yang
    Zhang, Jia-Tao
    Zeng, Kang-Hui
    Wu, Yi-Long
    [J]. LUNG CANCER, 2022, 172 : 160 - 169
  • [9] Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
    Ma, Weijie
    Zeng, Jie
    Chen, Shuai
    Lyu, Yue
    Toomey, Kyra A.
    Phan, Chinh T.
    Yoneda, Ken Y.
    Li, Tianhong
    [J]. BIOMARKER RESEARCH, 2021, 9 (01)
  • [10] Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
    Weijie Ma
    Jie Zeng
    Shuai Chen
    Yue Lyu
    Kyra A. Toomey
    Chinh T. Phan
    Ken Y. Yoneda
    Tianhong Li
    [J]. Biomarker Research, 9
12345